April 4, 2019 07:34 PM EDTUpdated May 28, 12:47 PM
Deals

To counter a law­suit, Bris­tol-My­ers out­lines how the big Cel­gene buy­out will show­er $187M-plus on Mor­gan Stan­ley

John Carroll

Editor & Founder

Any­one look­ing to see why in­vest­ment bankers love big time M&A so much should check out Bris­tol-My­ers Squibb’s new SEC fil­ing Thurs­day evening. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times